Moderate to severe atopic dermatitis in adults & adolescents ≥12 yr who are candidates for systemic therapy. Add-on maintenance treatment for severe asthma w/ type 2 inflammation characterised by raised blood eosinophils &/or raised FeNO in adults & adolescents ≥12 yr who are inadequately controlled w/ high dose inhaled corticosteroid (ICS) plus another medicinal product for maintenance treatment.
SCAtopic dermatitis Adult Initially 600 mg (two 300-mg inj consecutively administered at different inj site), followed by 300 mg every other wk. Adolescent weighing ≥60 kg Initially 600 mg, followed by 300 mg every other wk, <60 kg Initially 400 mg (two 200-mg inj consecutively administered at different inj site), followed by 200 mg every other wk. Asthma Adult & adolescent ≥12 yr Initially 400 mg, followed by 200 mg every other wk. Patients w/ severe asthma & who are on oral corticosteroids, patients w/ severe asthma & comorbid moderate to severe atopic dermatitis Initially 600 mg, followed by 300 mg every other wk.
Should not be used to treat acute asthma symptoms or acute exacerbations; acute bronchospasms or status asthmaticus. Discontinue immediately if systemic hypersensitivity reaction (immediate or delayed) occurs. Eosinophilic conditions in adult asthma patients. Patients w/ pre-existing helminth infections should be treated before initiating dupilumab. Conjunctivitis-related events. Atopic dermatitis patients w/ comorbid asthma. Do not concurrently give live & live attenuated vaccines. Patients w/ hepatic impairment or severe renal impairment. Pregnancy & lactation. Childn <12 yr.
Sign Out
